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A B S T R A C T
Animalmodels for seizures and epilepsy have played a fundamental role in advancing our understanding
of basic mechanisms underlying ictogenesis and epileptogenesis and have been instrumental in the
discovery and preclinical development of novel antiepileptic drugs (AEDs). However, there is growing
concern that the efﬁcacy of drug treatment of epilepsy has not substantially improved with the
introduction of new AEDs, which, at least in part, may be due to the fact that the same simple screening
models, i.e., themaximal electroshock seizure (MES) and s.c. pentylenetetrazole (PTZ) seizure tests, have
been used as gatekeepers in AED discovery for>6 decades. It has been argued that these old models may
identify only drugs that share characteristics with existing drugs, and are unlikely to have an effect on
refractory epilepsies. Indeed, accumulating evidence with several novel AEDs, including levetiracetan,
has shown that the MES and PTZ models do not identify all potential AEDs but instead may fail to
discover compounds that have great potential efﬁcacy butwork throughmechanisms not tested by these
models. Awareness of the limitations of acute seizure models comes at a critical crossroad. Clearly,
preclinical strategies of AED discovery and development need a conceptual shift that is moving away
from using models that identify therapies for the symptomatic treatment of epilepsy to those that may
be useful for identifying therapies that are more effective in the refractory population and that may
ultimately lead to an effective cure in susceptible individuals by interfering with the processes
underlying epilepsy. To realize this goal, the molecular mechanisms of the next generation of therapies
must necessarily evolve to include targets that contribute to epileptogenesis and pharmacoresistance in
relevant epilepsy models.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Despite the successful development of various new antiepi-
leptic drugs (AEDs) in recent decades, the search for new therapies
with better efﬁcacy and tolerability remains an important goal.1
The discovery and development of a newAED relies heavily on the
preclinical use of animal models to establish efﬁcacy and safety
prior to ﬁrst trials in humans.2 This approach has been very
successful and crucially contributed to the development of
numerous clinically effective AEDs. In the discovery and
development of new AEDs, animal models of seizures or epilepsy
serve a variety of purposes (Fig. 1). First, they are used for
identifying novel AEDs. Second, once the anticonvulsant activity* Correspondence address: Department of Pharmacology, Toxicology and
Pharmacy, University of Veterinary Medicine, Bu¨nteweg 17, D-30559 Hannover,
Germany. Tel.: +49 511 856 8721; fax: +49 511 953 8581.
E-mail address: wolfgang.loescher@tiho-hannover.de.
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.01.003of a novel compoundhas beendetected, animalmodels are used to
evaluate the possible speciﬁc efﬁcacies of the compound against
different types of seizures or epilepsy. Third, speciﬁc models of
AED-resistant seizures are used to investigate whether the novel
drug has advantages towards clinically established AEDs for
therapy of difﬁcult-to-treat types of seizures or epilepsies. Fourth,
animal models are used to characterize the preclinical efﬁcacy of
novel compounds during chronic administration. Such chronic
studies can serve different objectives, for instance evaluation of
whether drug efﬁcacy changes during prolonged treatment, e.g.
because of development of tolerance. Fifth, in view of the
possibility that chronic brain dysfunctions, such as epilepsy,
might lead to altered sensitivity to drug adverse effects, models
with epileptic animals are useful to study whether epileptogen-
esis alters the adverse effect potential of a given drug. Sixth,
animal models can be used to estimate effective plasma
concentrations of new AEDs for ﬁrst clinical trials. And ﬁnally,
seventh, animal models are crucial in discovering therapies that
may prevent or modify the development of epilepsy after brainvier Ltd. All rights reserved.
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Fig. 1. The main purposes of animal models of seizures or epilepsy in the discovery
and development of new AEDs. For details see text.
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this review.
Not all animal models of seizures and/or epilepsy can be used
for all of the above described purposes. Furthermore, the intention
of the experiment is essential for selection of a suitable animal
model. For instance, simple seizure models such as the maximal
electroshock seizure (MES) test, allowing to test high numbers of
compounds for anticonvulsant activity in relatively short time, will
be preferred above more complex models in screening approaches
of anticonvulsant drug development.
Most animal models used in epilepsy research are models of
epileptic seizures rather than models of epilepsy. Since epilepsy is
[()TD$FIG]
Models of epilepsy or e
Genetic animal models
Animals with 
spontaneous
recurrent seizures
Animals with 
reflex seizures
E
e.g., rats or mice with 
spike-wave
e.g., DBA/2 mice, 
GEPR gerbils
discharges (GAERS, 
tottering or  lethargic 
mice), epileptic dogs,
transgenic mice
, ,
photosensitive
baboons
Fig. 2. An overview of models of epilepsy or epileptic seizures. Note that there are num
spontaneous recurrent seizures develop after traumatic brain injury, ischemic brain dacharacterized by spontaneous recurrent seizures (SRS), a test such
as the MES test, in which an acute seizure is electrically induced in
a normal non-epileptic animal, cannot represent a model of
epilepsy. On the other hand, there are true models of epilepsy, for
instance animal mutants or transgenic animals with spontaneous-
ly recurrent seizures, which are obviously more closely related to
human epilepsy than mere seizure models (Fig. 2). Furthermore,
epileptogenesis resulting in SRS can be induced by chemical or
electrical means (Fig. 2). Unfortunately, researchers often do not
differentiate between animal models of epilepsy and animal
models of epileptic seizures although the difference may be
important in interpretation of data obtained with such models. Of
course, models of epilepsy, e.g. mutant animals with inherent
epilepsy, can be used as models of seizures, e.g. in anticonvulsant
drug potency studies, whereas a pure seizure model in a non-
epileptic animal can not be used as a model of chronic epilepsy.
Innumerable models of epilepsy and epileptic seizures have
been described.3 The various animal models can be assigned to
different categories, e.g. models with spontaneously occurring
seizures versus chemically or electrically induced seizures, models
with recurrent seizures vs. models with single seizures (i.e.,
chronic versus acute models), models with partial seizures versus
models with generalized seizures, modelswith convulsive seizures
versus models with nonconvulsive seizures, screening models
versus models for a more advanced phase of the screening
procedure (‘‘secondary screening’’), mechanism-related models
(i.e., with seizure induction by a knownmechanism) versusmodels
without a speciﬁc (or known) mechanism, and seizure threshold
models versus models with (supra)maximal or suprathreshold
induction of seizures.3,4pileptic seizures
I d ti f in uc on o  se zures
in normal animals
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erous models not shown in this ﬁgure, including chronic epilepsy models in which
mage, or febrile seizures. For more details see Lo¨scher3 and Pitka¨nen et al.8
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Fig. 3. An overview of models for speciﬁc types of epilepsy or epileptic seizures. As already noted in Fig. 2 legend, there are numerous models not shown in this ﬁgure,
including chronic epilepsymodels in which spontaneous partial seizures develop after traumatic brain injury, ischemic brain damage, or febrile seizures. Formore details see
Lo¨scher3 and Pitka¨nen et al.8
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models of epilepsy and epileptic seizures is shown in Fig. 2.
However, the clinical selection of an AED is based primarily on its
efﬁcacy for speciﬁc types of seizures and epilepsy, so that for the
purpose of preclinical drug evaluation, it may be more appropriate
to classify models on the basis of type of seizure or epilepsy as
shown in Fig. 3. This should also allow a more precise
interpretation of data from investigations into mechanisms of
any of these models and facilitate comparisons between experi-
mental and clinical data. This review will only deal with models
that are commonly used in AED discovery and development. For a
more detailed review of animal models of seizures or epilepsy and
their use in studying mechanisms underlying epileptogenesis and
ictogenesis, the interested reader is referred to several previous
reviews.3,5–9
2. Animal models used in AED discovery
For AED discovery, which necessitates screening of large
numbers of compounds, animal models should be easy-to-
perform, time- and cost-efﬁcient, and predictive of clinical activity.
This explains that two simple seizure models in mice and rats, the
MES and s.c. pentylenetetrazole (PTZ) tests, which have been
developed >60 years ago, are still the most widely used animal
seizuremodels employed in the search for new AEDs.1,2 In theMES
test, tonic–clonic seizures are induced by transcorneal or, less
often, transauricular application of a short (0.2 s) suprathreshold
electrical stimulus in normal mice (50 mA) or rats (150 mA). The
endpoint in this test is tonic hindlimb extension, and the test is
thought to be a predictive model for generalized tonic–clonic
seizures.10 In addition, it was proposed that the MES test may
predict AEDswith efﬁcacy against partial seizures,10 but the lack ofanti-MES efﬁcacy of several novel AEDs (e.g., levetiracetam,
tiagabine, vigabatrin) that subsequently were shown to suppress
partial seizures in epilepsy patients (Table 1) strongly argues
against this idea. Thus, true models of partial seizures have to be
included at subsequent stages of preclinical drug development (see
below).
In the s.c. PTZ (or metrazol) seizure test, the convulsive dose of
PTZ inducing a clonic seizure of at least 5 s duration in 97% of the
animals (CD97) is subcutaneously injected and animals are
observed for a post-injection period of usually 30 min for the
occurrence of such a ‘‘threshold’’ seizure. The test is thought to be
predictive of anticonvulsant drug activity against nonconvulsive
(absence or myoclonic) seizures.10 However, as shown in Table 1,
various AEDs that protect against nonconvulsive seizures in
epilepsy patients failed in the PTZ test, so that other models of
nonconvulsive seizures, including genetic rat mutants with
spontaneous nonconvulsive seizures, are needed for correct
prediction of AED efﬁcacy against this seizure type.4
3. Animal models used to assess the spectrum of
anticonvulsant activity of new AEDs
Once the efﬁcacy of an investigational AED is established using
simple screening models such as the MES or PTZ tests, a battery of
additional models is used to characterize further the anticonvul-
sant potential and spectrum of activity of this compound. Themost
often used model in this respect is the kindling model of temporal
lobe epilepsy (TLE). Whereas the MES and PTZ models induce
seizures in healthy, neurologically intact rodents, kindling is a
chronic model in which the repeated application of electrical
stimuli via a depth electrode in the limbic system (amygdala or
hippocampus) of rats induces permanently enhanced seizure
Table 1
Anticonvulsant spectrum of AEDs in models and man. ‘‘NE’’ = not effective.
Drug Anticonvulsant effect in rodent models Clinical efﬁcacy (seizure suppression)
MES (mice/rats) s.c. PTZ (mice/rats) Amygdala-kindling (rats, focal seizures) Partial seizures Generalized seizures
Convulsive Nonconvulsive
Predominant Na+ (and Ca2+) channel activity
Phenytoin + NE + + + NE
Carbamazepine + NE + + + NE
Oxcarbazepine + NE + + + NE
Lamotrigine +  + + + +
Zonisamide +  + + + +
Predominant Ca2+ channel activity
Ethosuximide NE + NE NE NE +
GABA systems
Benzodiazepines + + + + + +
Vigabatrin NE + + + + NE
Tiagabine NE + + + + NE
Mixed
Valproate + + + + + +
Felbamate + + + + + +
Topiramate + NE + + + +
Phenobarbital + + + + + 
Novel targets
Gabapentin   + + + NE
Pregabalin + NE + + + NE
Levetiracetam NE NE + + + 
Lacosamide + NE + +
Retigabine + + + +
Adapted from Rogawski and Lo¨scher45 and Bialer et al.41
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to those occurring in human TLE.11 The kindling model is the only
chronic model that is currently used by most AED discovery
programs, including the NIH/NINDS-sponsored anticonvulsant
drug development (ADD) program in the U.S.1 It is the only model
that adequately predicted the clinical utility of novel AEDs against
partial seizures in patients with epilepsy (Table 1). Approaches to
replace the classical kindling model, which is costly and laborious,
by easiermodels such as corneal kindling have not been successful,
because the predictivity of such models is not clear.
Various other models of seizures or epilepsy are employed in
subsequent steps of preclinical AED development, including
genetic models such as DBA/2 mice with audiogenic seizures
and rats mutants with spontaneously occurring spike-wave
absences in the EEG, such as the Strasbourg rat.2,4 Such models
are useful to elucidating the potency and spectrum of
anticonvulsant activities against different types of epileptic
seizures. They do, however, not allow evaluating whether the
new drug possesses a higher efﬁcacy for suppressing seizures
compared to clinically established AEDs, particularly in difﬁcult-
to-treat types of epilepsy.
4. Animal models for pharmacoresistant seizures
Despite the development of various new AEDs over the recent
20 years, the available evidence indicates that the efﬁcacy of drug
treatment of epilepsy has not substantially improved, but that still
about 30–40% of patients suffer from AED-resistant seizures.1,12,13
Thus, there is a need to identify and incorporate models of
refractory epilepsy into development of new AEDs.2,14 This idea is
not new15 but, surprisingly, has not been fully appreciated for
almost two decades. Based on the operational deﬁnition of AED
resistance in patients with epilepsy,16 the term ‘‘pharmacoresis-
tant’’ applied in the context of animal models can be deﬁned as
persistent seizure activity not responding or with very poor
response to monotherapy with at least two current AEDs atmaximum tolerated doses.17 Several models which fulﬁll this
deﬁnition have been developed in the last 20 years.14 In this
respect, two different approaches have been employed (Fig. 4).
One is to usemodels of seizures or epilepsy that per se are resistant
to antiepileptic effects of AEDs. An example is the 6-Hz
psychomotor seizure model in mice as a potential screen for
therapy-resistant epilepsy. In thismodel, which is used in the early
drug identiﬁcation studies by the ADD program at the University of
Utah (Fig. 5), electrical stimulation by low-frequency (6-Hz)
rectangular pulses of 0.2-ms duration delivered through corneal
electrodes for 3 s induces seizures that are reminiscent of
‘‘psychomotor seizures’’ occurring in human limbic epilepsy.18
At 22 mA, the convulsant current in 97% of the mice tested (CC97),
all AEDs examined in this model block the seizures, demonstrating
that the model does not discriminate between clinical classes of
AEDs at this current. However, when the current is increased to
twice the CC97 (i.e., 44 mA), most AEDs loose their efﬁcacy, and
only few AEDs, including levetiracetam (at high doses), valproate,
and novel AEDs such as brivaracetam and retigabine, allow
complete protection against the 6-Hz seizures (Fig. 4). Based on
these observations, it was suggested that the 6-Hz stimulationmay
provide a useful and rather inexpensivemodel of therapy-resistant
limbic seizures.18
Another, much more labor-intensive and expensive approach
is the use of chronic epilepsy models such as kindling (Fig. 4). In
the kindling model of TLE, repeated excitatory stimuli induce
partial and, later, secondarily generalized seizures that increase
in length and severity with continued stimulation. In the
amygdala-kindling model in rats, in which kindling is produced
by repeated electrical stimulation of the amygdala, exposure to
low doses of lamotrigine during kindling development leads to a
reduced subsequent anticonvulsant response to the drug in fully
kindled animals.19 The same observation was reported for
kindling with pentylenetetrazole.20 Lamotrigine-refractory kin-
dled rats are also resistant to carbamazepine, phenytoin and
topiramate, but not valproate, felbamate and retigabine.21 It was
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Fig. 4. Different categories of mouse and rat models of AED-resistant seizures and epilepsy. For details see text and Lo¨scher14,21 and Bialer et al.41
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model of drug-refractory epilepsy.2 However, in view of the fact
that loss of efﬁcacy (tolerance) develops upon prolonged
exposure to several AEDs, including lamotrigine, the loss of
efﬁcacy of several AEDs in lamotrigine-resistant rats could be a
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patients with epilepsy.22
In patients, seizure activity associated with cortical dysplasia is
often resistant to commonly used AEDs.23 In rats, exposure to
treatment with the antimitotic agent methylazoxymethanol
acetate (MAM) in utero produces a neuronal migration disorder
similar to the cortical dysplasias seen in human brain.24 In such
MAM-exposed rats, seizures induced by either kainate or the
cholesterol biosynthesis inhibitor AY-9944 are refractory to
valproate, ethosuximide or carbamazepine (Fig. 4). Thus, these
rats seem to provide a two-hit model of refractory seizures.
An alternative approach to develop animal models of drug-
resistant epilepsy is the treatment of large group of kindled or
epileptic rats with AEDs and subsequent selection of subgroups
of animals that either respond or do not respond to this
treatment (Fig. 4). An animal model of epilepsy allowing
selection of subgroups of animals with drug-refractory and drug-
responsive seizures could be a valuable tool to study why and
how seizures become intractable and to develop more effective
treatment strategies. Two models that allow such subgroup
selection have been developed and characterized by my group
[cf., 14,25].
We became interested in developing such animal models >20
years ago,15 leading to the discovery of phenytoin-resistant
subgroups of amygdala-kindled Wistar rats (Fig. 4). By repeated
testing of the anticonvulsant effect of phenytoin in large groups of
rats of the Wistar outbred strain, we found that the individual
response of fully kindled rats to phenytoin differs, that is that
kindled seizures in some animals consistently respond and others
never respond to phenytoin.26 In recent years, we have repeated
the selection of phenytoin responders and nonresponders in
kindled Wistar rats several times, using either phenytoin or its
prodrug fosphenytoin for selection. Average data from more than
200 rats show a consistent anticonvulsant response to phenytoin
in only about 20% of the animals, no anticonvulsant response in
another 20%, and a variable response in the remaining 60%. Based
on our data, we suggest that the three subgroups of amygdala-
kindled rats model three different clinical scenarios.14 The
nonresponder subgroup models drug-refractory patients with
TLE in which AED treatment does not signiﬁcantly reduce seizure
frequency. The variable responder group model patients in which
AED treatment reduces seizure frequency but does not achieve
complete control of seizures. The responder subgroup models
patients which achieve complete control of seizures during AED
treatment.
Following the identiﬁcation of phenytoin resistant kindled
Wistar rats, most clinically available AEDs were tested in such
animals. Except the novel drug levetiracetam, all examined AEDs
were signiﬁcantly less efﬁcacious or not efﬁcacious at all in
phenytoin nonresponders compared to phenytoin responders,
demonstrating that the phenytoin resistance of a subgroup of
kindled Wistar rats extends to various other old and new AEDs.14
This reﬂects the clinical situation in patients with TLE, because
most patients who are refractory to one AED are also resistant to
other AEDs, including newly developed drugs.
Stimulated by the ﬁndings in the kindling model, we started
studyingwhether pharmacoresistant rats can also be selected from
TLEmodelswith SRS. In post-status epilepticus (post-SE)models of
TLE, a chemically or electrically induced SE is followed, after a
latent period, by SRS.17 This group of models is often considered to
have the greatest parallels with human TLE, but until recently only
few studies examined the pharmacological responsiveness of the
spontaneous seizures in these models. One obvious reason is that
drug efﬁcacy testing in rats with SRS is technically difﬁcult,
expensive, and time-consuming, because AEDs have to be
administered over a prolonged period, taking into account themarked differences in elimination kinetics between rodents and
humans,27 and rats have to be recorded continuously by video/EEG
monitoring during this period for the occurrence of seizures, to
allow comparison of seizure frequency during treatment with
seizure frequency in control periods.
In the pilocarpine model of TLE in Wistar rats, prolonged
administration of levetiracetam via osmotic minipumps resulted
in a large inter-individual variation in drug response.28 About 40%
of the epileptic rats were responders with complete or almost
complete control of spontaneous seizures, another 40% were
nonresponders, and the remaining rats could not clearly be
included in either group because of variation between pre- and
postdrug control seizure frequency. Prompted by these promising
data from the pilocarpine model, we investigated whether
responders and nonresponders also occur in another post-SE
model of TLE.29 In this model, SE is induced by prolonged electrical
stimulation of the basolateral amygdala (BLA), which leads to
development of SRS in >90% of the animals. Prolonged treatment
of epileptic Sprague–Dawley rats with phenobarbital at maximal
tolerated doses resulted in two subgroups, responders and
nonresponders.29 In two independent studies in 11 and 15
epileptic rats, 36 and 40% of the rats were resistant to treatment
with phenobarbital, demonstrating the reproducibility of this
model.14 When the phenobarbital-resistant rats were subsequent-
ly treated with phenytoin, 83% of these rats were also resistant to
the latter drug (Fig. 4), thus fulﬁlling the minimum requirements
for a model of drug-resistant epilepsy described above. Plasma
drug levels and adverse effects of phenobarbital and phenytoin
were comparable in responders and nonresponders, demonstrat-
ing that the resistance is restricted to the anticonvulsant effect of
these AEDs. The severity or duration of the initial brain insult (the
SE) did not differ between responders and nonresponders,
indicating that the different AED response in the two subgroups
is genetically determined.
Epilepsy models allowing selection of AED responders and
nonresponders are an ideal tool to investigate mechanisms of AED
resistance.14 Fig. 6 summarizies the most important differences
between AED responders and nonresponders in the kindling and
post-SE TLE models that we determined in recent years.14,21
Several of our ﬁndings are in line with clinical ﬁndings in patients
with AED resistant seizures, including high frequency of SRS,
psychopathology, and hippocampal damage as poor prognostic
factors for treatment, alterations in AED targets in resistant
individuals, and a role of genetic factors (Fig. 6). Interestingly, the
only common ﬁnding in both models was increased expression of
the efﬂux (‘‘multidrug’’) transporter P-glycoprotein in brain
capillary endothelial cells that form the blood–brain barrier,
which has also been described in epileptogenic brain tissue of
patients undergoing resective surgery, andmay be associated with
lower brain concentrations of various AEDs by increased efﬂux
from the brain.30
5. Evaluation whether efﬁcacy of new AEDs changes during
chronic treatment
In most seizure models, investigational drugs are tested after
administration of a single dose and the drug effect is then
determined at one ﬁxed time point (e.g., 30 min) following drug
administration. However, treatment of patients with epilepsy is
typically by chronic, daily drug administration, which may change
drug efﬁcacy. There are different scenarios in the respect. (1) With
some drugs the anticonvulsant efﬁcacy increases during prolonged
treatment4; examples are primidone (due to accumulation of
phenobarbital), valproic acid (reasons are unknown), and vigaba-
trin (due to accumulation of GABA by irreversible inhibition of its
degradation). Consequently, determination of acute potency of
[()TD$FIG]
Fig. 6. Differences between AED-responders and–nonresponders in animal models of drug-resistant epilepsy. For details see Lo¨scher.14,21
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treatment and, in case of new compounds, may thus lead to false
decisions with respect to further preclinical or clinical develop-
ment.27
(2) With several AEDs, particularly benzodiazepines, the
anticonvulsant efﬁcacy decreases during prolonged treatment
due to development of adaptive processes (‘functional tolerance’)
in the brain.22 With some older AEDs, such as phenobarbital,
carbamazepine or phenytoin, also ‘‘metabolic tolerance’’ may
occur due to enhanced drug elimination by induction of AED
metabolizing enzymes. Tolerance is clinically advantageous when
it concerns the adverse effects of AEDs but disadvantageous when
it involves the antiepileptic efﬁcacy itself. In mice and rats,
tolerance to the anticonvulsant and adverse effect of benzodia-
zepines and various other AEDs can be demonstrated in a variety of
models of seizures or epilepsy with 1–4 weeks of daily drug
administration, provided that effective drug concentrations are
maintained during treatment.22 In addition to benzodiazepines,
evidence for loss of efﬁcacy of those old and new AEDs for which
functional tolerance was shown in animal models has also been
reported in a small portion of patients with epilepsy, which should
be taken into account when considering mechanisms of AED
resistance.22
6. Comparison of adverse effects of new AEDs in epileptic vs.
nonepileptic animals
A crucial parameter deciding the clinical utility of new AEDs
during preclinical development is the therapeutic (or protective)
index expressing the margin between anticonvulsant and adverse
effects.4,10,31 ‘‘Neurotoxic’’ adverse effects such as motor im-
pairment or sedation are commonly quantiﬁed during preclinical
testing by simple models such as the rotarod test in normal,
healthy rodents. However, the validity of using normal animals for
adverse effect predictions in epilepsy patients is questionable,
because the chronic brain alterations associatedwith epilepsymay
affect the tolerability of AEDs. Limbic kindling of rodents induced
by corneal kindling of mice and amygdala kindling of rats conﬁrmthat animals with epileptogenic brain alterations are more
susceptible to the behavioral and cognitive alterations following
acute administration of certain established AEDs and investiga-
tional drugs, such as N-methyl-D-aspartate (NMDA) receptor
antagonists.31–33 Similar ﬁndings have been reported for genetic
absence epilepsy-prone rats, in which certain AEDs also are
associated with a more marked deterioration of motor function
than in normal animals.31 This appears in line with several
complications with AED use in man being linked to an interaction
with the dysfunction of the brain imposed by the epileptic
condition.31 Furthermore, adverse effect testing in kindled rats
correctly predicted the unexpected serious adverse effects
associated with competitive NMDA antagonists in epilepsy
patients but not healthy volunteers.34 Thus, it is important to
involve epileptic animals in preclinical adverse effect testing, in
particular when evaluating new AED candidates with novel or
unknown mechanisms. In that respect, limbic kindling appears to
represent a sensitive and relevant approach.
7. Estimation of effective plasma concentrations of new AEDs
for ﬁrst clinical trials
Because rodents eliminate most drugs much more rapidly than
humans, anticonvulsant doses of AEDs (in mg/kg body weight) are
usually much higher in rodent models of seizures or epilepsy than
effective doses in epilepsy patients.27 However, determination of
effective AED plasmas levels in rodents after acute or chronic drug
administration has demonstrated that effective plasma AED levels
are remarkably similar in humans and rats.27 Thus, plasma levels
determined at time of anticonvulsant effect in rodent models can
be used for selecting adequate doses of a new AED for ﬁrst clinical
trials by calculating the doses that will produce such plasma levels
in humans. Of course, many other details, including toxicity, have
to be dealt withwhen selecting doses of an investigational drug for
ﬁrst use in humans, but, in view of the critical problems associated
with dose ﬁnding in epilepsy patients, the information obtained by
plasma level determinations in preclinical seizure models should
at least be considered.
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The search for new AEDs has traditionally been directed to
compounds that suppress seizures in a symptomatic fashion.
There is no clinical evidence that any AED is capable of preventing
or modifying epilepsy after brain insults, such as traumatic brain
injury (TBI).35 In view of the complex molecular, morphological
and functional alterations that are induced by brain insults and
thought to be involved in the epileptogenic process leading to
epilepsy, drugs that interfere with these alterations will most
likely act by other mechanisms than AEDs that suppress seizures.
As yet, prevention of epilepsy in patients at risk is an unmet
clinical need, but various strategies for epilepsy prevention or
disease-modiﬁcation are evaluated in animal models. The most
widely usedmodels in this respect are kindling, post-SEmodels of
TLE, and models of TBI.36–38 Drug testing in such models sharply
differs from testing of novel AEDs as illustrated in Fig. 5, in that
drugs with potential anti-epileptogenic efﬁcacy are tested
immediately after the brain insult, before SRS occur.39 A typical
protocol for antiepileptogenesis testing in post-SE rats models of
TLE is shown in Fig. 7. There is an enormous effort by several
groups in the ﬁeld to develop new strategies for antiepileptogen-
esis, and the progressively enhanced understanding of mechan-
isms underlying epileptogenesis will hopefully soon lead to
effective treatments.38
9. Why has testing in animal models not provided more
effective AEDs?
There is growing concern that the efﬁcacy of drug treatment of
epilepsy has not substantially improved with the introduction of
new AEDs.12,13,40 This current dilemma of AED development has
led to increasing disappointment among clinicians, basic scientists,
and industry and may halt any further improvement in thetreatment of epilepsy unless we ﬁnd ways out of this dilemma.
What are the reasons for this apparent failure of modern AED
development to discover drugs with higher efﬁcacy? One major
reason is certainly the fact that, with few exceptions, all AEDs have
been discovered by the same conventional animal models,
particularly the MES test in rodents, which served as a critical
gatekeeper. These tests have led to useful new AEDs, but obviously
did not help developing AEDs with higher efﬁcacy in as yet AED-
resistant patients. This concern is not new but, surprisingly, has
largely been unappreciated for several decades. A logical conse-
quence would be to include models of AED resistant seizures, such
as the 6-Hz test in mice or phenytoin-resistant kindled rats, in AED
development, but this has started only recently.2 For instance, as
illustrated in Fig. 5, the 6-Hz test is now included in the initial drug
screening of the ADD program to avoid that effective drugs such as
levetiracetam, which do not act in the MES and PTZ models but
show efﬁcacy in the 6-Hz model, are falsely considered inactive in
the early evaluation process. However, whether this problem can
be minimized by the 6-Hz test is currently not known, because
levetiracetam was only retrospectively identiﬁed by this test.
Furthermore, the fact that novel AEDs such as brivaracetam and
carisbamate are highly effective in the 6-Hz test41 but recently
failed to exhibit any robust efﬁcacy in phase III clinical trials casts
doubt onwhether the 6-Hz test is really the best availablemodel in
the search for more effective AEDs. Rather a battery of models of
AED resistant seizures as illustrated in Fig. 4 should be included in
the development of novel AEDs to concentrate on drugs that
exhibit clear advantages in efﬁcacy towards established com-
pounds.
Another argument that has recently been raised is that the
seizure types used as endpoints in the MES, kindling and other
models included in current AED screening programsmay primarily
result in the development of new, but redundant drugs that
primarily target convulsive (e.g., tonic–clonic) seizures.42 This is a
result of current deﬁnitions of experimental seizures that often
W. Lo¨scher / Seizure 20 (2011) 359–368 367focus on speciﬁc types of motor seizures with a deﬁned minimum
duration, but tend to ignore short nonconvulsive seizures, which
often resemble human complex-partial seizures more than those
seizure types used as endpoints for drug testing. Thus, during
screening of potential AEDs, new agents that may control human
complex-partial seizures more effectively than existing AEDs
might be missed.42
Another important point is that the typical approach of AED
testing in animalmodels primarily focuses on drug potency and not
efﬁcacy. Thus, different investigational drugs are compared in
terms of their anticonvulsant ED50s, i.e., the dose suppressing
seizures in 50% of the animals, which is calculated from dose–
response curves, testing one group of animals per dose. The lower
the ED50, the more potent is the drug, and high potency is often an
important argument for selecting drugs for further development.
However, it is the antiepileptic efﬁcacy which ﬁnally determines
the clinical usefulness of a new AED and should be considered
during preclinical drug testing.
Finally, current strategies of AED development search for
drugs that symptomatically suppress seizures by diverse
mechanisms. It is unlikely that anticonvulsant efﬁcacy can be
markedly enhanced by any of the new mechanisms of seizure
suppression of those numerous investigational drugs that are
currently in the AED pipeline.1,13,41 Instead, one may argue that
progress in the efﬁcacy of AEDs, particular with regard to
pharmacological treatment of drug-resistant epilepsy, will not
be made unless and until we develop drugs that speciﬁcally
target the underlying disease. Indeed, already in 2001, a
workshop organized by the NINDS to explore the current
problems, needs, and potential usefulness of existing methods of
discovery of new therapies to treat epilepsy patients concluded
that the epilepsy research community should undergo a
conceptual shift to move away from using models that identify
therapies for the symptomatic treatment of epilepsy to those
that may be useful for identifying therapies that are more
effective in the refractory population and that may ultimately
lead to an effective cure in susceptible individuals.36 To realize
the goal of a cure, the molecular mechanisms of the next
generation of therapies must necessarily evolve to include
targets that contribute to epileptogenesis and pharmacoresis-
tance in relevant epilepsy models.
10. Conclusions
The new, third generation AEDs, which have been discovered
by testing of large numbers of investigational compounds in
animal models over the last 20 years, have undoubtedly
expanded the therapeutic options, in particular for those in
need for a change in medical regimen.1 However, the efﬁcacy of
these new AEDs for treatment of new-onset epilepsy is at best
similar to that of older AEDs.13,40 New AEDs have other beneﬁts
over some of the older drugs for epilepsy in that treatment with
some of the new AEDs avoids adverse drug interactions and
hypersensitivity reactions43 and some new AEDs have clinically
important utility for disorders other than epilepsy.44 However,
the major goal of AED discovery and development should be
more effective treatments for the AED-resistant epilepsy
patients. For this goal, we need new concepts and fresh thinking
about how to radically change and improve AED discovery and
development. Studies in animal models have signiﬁcantly
contributed to our understanding of ictogenesis and epilepto-
genesis and how AEDs act to suppress seizures.8 Furthermore,
they are indispensable in the preclinical discovery and develop-
ment of novel AEDs.1 However, the current strategies and
concepts of preclinical AED development need to be radically
overhauled.Acknowledgements
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